216 related articles for article (PubMed ID: 12238579)
1. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.
Levie K; Gjorup I; Skinhøj P; Stoffel M
Scand J Infect Dis; 2002; 34(8):610-4. PubMed ID: 12238579
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
[TBL] [Abstract][Full Text] [Related]
5. A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years.
Kurugöl Z; Mutlubaş F; Ozacar T
Vaccine; 2005 Apr; 23(22):2876-80. PubMed ID: 15780736
[TBL] [Abstract][Full Text] [Related]
6. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule.
Connor BA; Blatter MM; Beran J; Zou B; Trofa AF
J Travel Med; 2007; 14(1):9-15. PubMed ID: 17241248
[TBL] [Abstract][Full Text] [Related]
7. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
Gunn TR; Bosley A; Woodfield DG
N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial.
Heron L; Selnikova O; Moiseieva A; Van Damme P; van der Wielen M; Levie K; Hoet B; Stoffel M
Vaccine; 2007 Apr; 25(15):2817-22. PubMed ID: 17276552
[TBL] [Abstract][Full Text] [Related]
9. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
[TBL] [Abstract][Full Text] [Related]
11. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
[TBL] [Abstract][Full Text] [Related]
12. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination.
Young MD; Gooch WM; Zuckerman AJ; Du W; Dickson B; Maddrey WC
J Med Virol; 2001 Jul; 64(3):290-8. PubMed ID: 11424117
[TBL] [Abstract][Full Text] [Related]
14. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a rapid hepatitis B immunization schedule to the standard schedule for adults.
Marsano LS; Greenberg RN; Kirkpatrick RB; Zetterman RK; Christiansen A; Smith DJ; DeMedina MD; Schiff ER
Am J Gastroenterol; 1996 Jan; 91(1):111-5. PubMed ID: 8561109
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
Gilbert CL; Stek JE; Villa G; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
Vaccine; 2014 Nov; 32(48):6521-6. PubMed ID: 25252192
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients.
Tung J; Carlisle E; Smieja M; Kim PT; Lee CH
Am J Kidney Dis; 2010 Oct; 56(4):713-9. PubMed ID: 20630640
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of HBV vaccine during stated shelf-life.
Gloriani NG; Srinivasa K; Bock HL; Hoet B
Southeast Asian J Trop Med Public Health; 2010 Jul; 41(4):876-82. PubMed ID: 21073062
[TBL] [Abstract][Full Text] [Related]
19. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
